Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

DOW Chemical at the World Drug Delivery & Formulation Summit 2013

Published: Monday, December 10, 2012
Last Updated: Monday, December 10, 2012
Bookmark and Share
The pharmaceutical industry is experiencing a massive paradigm shift as the era of the highly profitable blockbusters comes to a close.

In an attempt to remain competitive, companies are under more pressure than ever to push novel compounds through the development pipeline and so it has been largely left to those in formulation and delivery to optimise their product portfolio using winning business strategies and leading technologies.

Entering its 4th consecutive year, the World Drug Delivery & Formulation Summit informs attendees of leading industry updates, strategies and technologies through technical workshops, case studies and presentations. It equips delegates with the tools and the know-how they need to launch new products, reformulate existing drugs and to remain both patient and regulatory compliant.

The three day summit is structured into three distinct streams that focus on leading issues and challenges in the small molecule, biological and technology space respectively. These include innovative formulation technologies, routes of delivery, advances in drug delivery devices and best practices in supporting the sourcing and management of partnering relationships.

We are thrilled that Dow Chemical will be attending both as our Lead Category Sponsor for Solubilisation and as Chairman for our leading technology day. We look forward to hearing from them during their interactive session on Monday 18th February 2013.

Exclusive sessions include:

•    Preventing the Demise of the Research-driven Pharmaceutical Industry Model
•    Driving Development in Extreme Population Groups – Geriatrics & Paediatrics
•    Evolving Controlled Release Technologies to Support the Next Generation of Drug Delivery
•    Novel Concepts in Pharmaceutical Analysis in Supporting Formulation
•    Understanding and Developing the Science Behind Oral Protein Delivery
•    Optimising the Delivery of Peptide Therapeutics
•    Adopting Open Innovation to Ensure Continued Growth and Success in Pharma Development

For the full programme, visit www.ddfevent.comprogramme.

This summit agenda is researched and produced with the help of drug delivery and formulation experts to reflect the latest industry news, technologies and advancements.  Additionally we facilitate pre-arranged one-to-one meetings onsite between yourselves and leading service and technology providers, hand-picked to suit your personal needs.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Over 70 Confirmed Delegates for North America’s Leading Biopharmaceutical Event
Less than 9 weeks away, North America’s leading biopharmaceutical event, Biomanufacturing Summit 2011, has officially released the latest list of confirmed registrants – an impressive line up of over 70 senior delegates.
Thursday, December 02, 2010
Uncover Tomorrow’s Biopharmaceutical Strategies to Enhance Capacity and Reduce Costs
Introducing North America’s leading biopharmaceutical event that will unveil the latest strategies and technologies available to improve your operations and equip you with the tools needed to thrive in an increasingly competitive environment.
Friday, October 29, 2010
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
A Cellular Symphony Responsible for Autoimmune Disease
Broad Institute researchers have used a novel approach to increase our understanding of the immune system as a whole.
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Editing of LIMS Data Made Faster and More Efficient in Matrix Gemini
The latest version of the Matrix Gemini LIMS (Laboratory Information Management System) from Autoscribe Informatics now provides faster and more efficient editing of LIMS data by eliminating the need for a second editing screen.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Red Clover Genome to Help Restore Sustainable Farming
The Genome Analysis Centre (TGAC) in collaboration with IBERS, has sequenced and assembled the DNA of red clover to help breeders improve the beneficial traits of this important forage crop.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos